NASDAQ$NUVL
Nuvalent Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Nuvalent highlighted pipeline progress and reported fourth quarter and full year 2023 financial results.
Nuvalent reported its Q4 and full year 2023 financial results, highlighting pipeline progress and reiterating key anticipated milestones. The company's cash position is expected to fund operations into 2027.
- FDA granted breakthrough therapy designation to NVL-520 for ROS1-positive metastatic non-small cell lung cancer (NSCLC).
- Phase 2 portion of ALKOVE-1 trial of NVL-655 initiated for advanced ALK-positive NSCLC.
- Updated data from ARROS-1 and ALKOVE-1 trials expected to be shared at medical meetings in 2024.
- Phase 1 trial for HER2 program expected to be initiated in 2024.
Headline financials
Revenue & EPS history
Nuvalent · Revenue · Quarterly
$0
Forward guidance
Nuvalent plans to execute on global registrational strategies, progress the Phase 2 portions of its ARROS-1 and ALKOVE-1 trials, launch the front-line development strategy for its ALK program, present interim data from ongoing clinical trials, and initiate the Phase 1 trial for its HER2 program.
Tailwinds
- Progress the Phase 2 portion of its ARROS-1 trial of NVL-520 in patients with advanced ROS1-positive NSCLC with registrational intent.
- Initiate the Phase 2 portion of its ALKOVE-1 trial of NVL-655 in patients with advanced ALK-positive NSCLC with registrational intent.
- Launch the front-line development strategy for its ALK program.
- Present interim data from its ongoing ARROS-1 and ALKOVE-1 clinical trials at medical meetings.
- Initiate the Phase 1 trial for its HER2 program.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2023
-0.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-7.7%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+14.6%
Q4 2021
Best reaction
-5.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.5% | -4.1% | -7.5% | |
| Q3 2025 | -5.0% | -11.6% | +6.2% | |
| Q1 2025 | +3.2% | +3.7% | +10.2% | |
| Q4 2024 | -2.8% | -7.0% | -5.2% | |
| Q3 2024 | -4.3% | -8.0% | -8.0% | |
| Q1 2024 | -3.1% | +0.7% | +17.2% | |
| Q4 2023 | -1.4% | +0.6% | -13.3% | |
| Q3 2023 | +3.7% | +5.0% | +38.8% | |
| Q2 2023 | -1.1% | -3.1% | +9.2% | |
| Q1 2023 | -2.5% | -1.1% | +3.5% | |
| Q4 2022 | +8.3% | +4.7% | +0.9% | |
| Q3 2022 | +1.0% | +2.9% | -2.1% | |
| Q2 2022 | +4.5% | +9.3% | +13.1% | |
| Q1 2022 | -0.7% | +7.3% | +16.1% | |
| Q4 2021 | +14.6% | +20.2% | -8.1% | |
| Q3 2020 | +1.3% | -14.7% | -2.4% | |
| Q3 2021 | +1.3% | -10.4% | -20.1% | |
| Q2 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2021 | -4.3% | -2.9% | -52.6% | |
| Q2 2021 | -4.3% | -2.9% | -52.6% | |
| Q4 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro